Cargando…

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus

AIMS: Therapy-related consequences of treatment for type 1 diabetes mellitus (T1DM), such as weight gain and hypoglycaemia, act as a barrier to attaining optimal glycaemic control, indirectly influencing the incidence of vascular complications and associated morbidity and mortality. This study quant...

Descripción completa

Detalles Bibliográficos
Autores principales:	McEwan, Phil, Bennett, Hayley, Fellows, Jonathan, Priaulx, Jennifer, Bergenheim, Klas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025276/ https://www.ncbi.nlm.nih.gov/pubmed/27632534 http://dx.doi.org/10.1371/journal.pone.0162441

Ejemplares similares

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
por: Bennett, Hayley, et al.
Publicado: (2014)

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
por: McEwan, Philip, et al.
Publicado: (2015)

Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA(1c), weight and hypoglycaemic event incidence
por: McEwan, P., et al.
Publicado: (2018)

The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability
por: Waeschle, Reiner M, et al.
Publicado: (2008)

Impaired awareness of hypoglycaemia in women with type 1 diabetes in pregnancy: Hypoglycaemia fear, glycaemic and pregnancy outcomes
por: Bahrami, Jasmine, et al.
Publicado: (2022)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Early hypoglycaemia and hyperglycaemia and 'tight' glycaemic control with and without glucose infusions
por: Raobaikady, R, et al.
Publicado: (2004)

Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C
por: McEwan, Phil, et al.
Publicado: (2015)

Factors influencing glycaemic stability after neonatal hypoglycaemia and relationship to neurodevelopmental outcome
por: Burakevych, Nataliia, et al.
Publicado: (2019)

Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control – Continuous Glucose Monitoring is the Solution
por: Adolfsson, Peter, et al.
Publicado: (2018)

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
por: Evans, Marc, et al.
Publicado: (2019)

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme
por: DeVries, J. Hans, et al.
Publicado: (2018)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM
por: Renard, Eric, et al.
Publicado: (2021)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

Effect of intensive glycaemic control on moderate hypoglycaemia and ICU length of stay in severe traumatic brain injury
por: Núñez-Patiño, Rafael A., et al.
Publicado: (2018)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Prevalence of Hypoglycaemia among Insulin-Treated Pregnant Women with Diabetes Who Achieved Tight Glycaemic Control
por: Ng, Danish, et al.
Publicado: (2019)

Correlations between parameters of glycaemic variability and foetal growth, neonatal hypoglycaemia and hyperbilirubinemia in women with gestational diabetes
por: Blasi, Immacolata, et al.
Publicado: (2023)

Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections
por: Bennett, Hayley, et al.
Publicado: (2015)

Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan
por: Matsumoto, Tetsuya, et al.
Publicado: (2021)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

Approach to assessing the economic impact of insulin‐related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool
por: Parekh, W. A., et al.
Publicado: (2015)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Severe neonatal hypoglycaemia and intrapartum glycaemic control in pregnancies complicated by type 1, type 2 and gestational diabetes
por: Yamamoto, J. M., et al.
Publicado: (2019)

Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
por: Soares, Ana Rita, et al.
Publicado: (2023)

Oxidised Met(147) of human serum albumin is a biomarker of oxidative stress, reflecting glycaemic fluctuations and hypoglycaemia in diabetes
por: Momozono, Akari, et al.
Publicado: (2020)

Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review
por: Verhulst, Clementine E. M., et al.
Publicado: (2022)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status
por: Wiegers, Evita C., et al.
Publicado: (2019)

Hypoglycæmia
Publicado: (1934)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Rates of glycaemic deterioration in a real-world population with type 2 diabetes
por: Donnelly, Louise A., et al.
Publicado: (2017)

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
por: Bergenstal, R M, et al.
Publicado: (2013)

Development and validation of the hypoglycaemia problem-solving scale for people with diabetes mellitus
por: Wu, Fei-Ling, et al.
Publicado: (2016)

Colesevelam‐induced hypoglycaemia in a patient with type 1 diabetes mellitus
por: Pavlou, Panagiotis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vap6riu9hl6uofevc8tcn1c13b